Vitrafy Life Sciences Limited
VFY.ASXHealth Care
Market Data
$3.500
-0.1%$0.00
-100000.0x
$-0.181
0.00%
+0.4%
Latest Earnings
FY26 Appendix 4E and Annual Report
4 August 2026
Vitrafy Life Sciences achieved 80% revenue growth to $3.7M in FY26, while reducing net losses by 50.6% to $16.2M, demonstrating progress toward commercialization with successful U.S. Army validation of its cryopreservation technology and strategic partnerships with major blood networks. The company raised $30M in capital and maintains a strong cash position of $41.2M, positioning itself for FDA registration and manufacturing scale-up in FY27. Key points: Phase II in-vitro platelet study with U.S. Army Institute of Surgical Research successfully completed across 20 donors at commercial volumes, with all protocols meeting or exceeding regulatory guidelines; no-wash protocol achieved 94% mean post-thaw platelet recovery; Strategic partnerships secured with Vitalant Innovation Center (2nd largest U.S. blood network, ~10% of collection market, 125+ sites, 900+ hospitals) and Hoxworth Blood Center to address end-of-life legacy red blood cell cryopreservation technology; Revenue growth of 80% to $3.66M and net loss reduction of 50.6% to $16.17M demonstrates progress toward profitability and validates commercialization pathway
Recent Announcements
FY26 Full Year Results Presentation
This is Vitrafy Life Sciences' FY2026 full year results presentation (not a substantial shareholder notice). The company reported $169k in animal health revenue (up 159% YoY), achieved USAISR Phase II validation with 94.4% platelet recovery, signed partnerships with blood collection organizations Vitalant and Hoxworth, and raised $30m in capital, closing with $41.2m in cash and term deposits.
FY26 Appendix 4E and Annual Report
Vitrafy Life Sciences achieved 80% revenue growth to $3.7M in FY26, while reducing net losses by 50.6% to $16.2M, demonstrating progress toward commercialization with successful U.S. Army validation of its cryopreservation technology and strategic partnerships with major blood networks. The company raised $30M in capital and maintains a strong cash position of $41.2M, positioning itself for FDA registration and manufacturing scale-up in FY27. Key points: Phase II in-vitro platelet study with U.S. Army Institute of Surgical Research successfully completed across 20 donors at commercial volumes, with all protocols meeting or exceeding regulatory guidelines; no-wash protocol achieved 94% mean post-thaw platelet recovery; Strategic partnerships secured with Vitalant Innovation Center (2nd largest U.S. blood network, ~10% of collection market, 125+ sites, 900+ hospitals) and Hoxworth Blood Center to address end-of-life legacy red blood cell cryopreservation technology; Revenue growth of 80% to $3.66M and net loss reduction of 50.6% to $16.17M demonstrates progress toward profitability and validates commercialization pathway
Get real-time alerts for VFY
Receive AI-powered earnings summaries and instant notifications when Vitrafy Life Sciences Limited releases results.
Register Free